79 related articles for article (PubMed ID: 27699032)
41. The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects.
Itamura H; Shindo T; Tawara I; Kubota Y; Kariya R; Okada S; Komanduri KV; Kimura S
JCI Insight; 2016 Jul; 1(10):e86331. PubMed ID: 27699218
[TBL] [Abstract][Full Text] [Related]
42. A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study.
Shimomura M; Shinozaki K; Hinoi T; Yoshimitsu M; Kurayoshi M; Sumitani D; Ishizaki Y; Oshiro T; Kodama S; Shimizu Y; Arita M; Tokunaga M; Yoshida M; Tanaka J; Ohdan H;
Springerplus; 2016; 5(1):1800. PubMed ID: 27803845
[TBL] [Abstract][Full Text] [Related]
43. Antitumor effects of bevacizumab in combination with fluoropyrimidine drugs on human oral squamous cell carcinoma.
Itashiki Y; Harada K; Takenawa T; Ferdous T; Ueyama Y; Mishima K
Oncol Lett; 2021 Oct; 22(4):730. PubMed ID: 34429770
[TBL] [Abstract][Full Text] [Related]
44. A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study.
Guo Y; Zheng T; Zhang C; Zhang Y
J Cancer; 2020; 11(7):1839-1845. PubMed ID: 32194795
[No Abstract] [Full Text] [Related]
45. Salidroside could enhance the cytotoxic effect of L‑OHP on colorectal cancer cells.
Shi X; Zhao W; Yang Y; Wu S; Lv B
Mol Med Rep; 2018 Jan; 17(1):51-58. PubMed ID: 29115408
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer.
Suzuki S; Shimazaki J; Morishita K; Koike N; Harada N; Hayashi T; Suzuki M
Mol Clin Oncol; 2016 Oct; 5(4):391-394. PubMed ID: 27699032
[TBL] [Abstract][Full Text] [Related]
47. Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.
Petrioli R; Francini E; Cherri S; Torre P; Fiaschi AI; Miano ST; Marrelli D; Rovello F; Francini G
Clin Colorectal Cancer; 2018 Dec; 17(4):e663-e669. PubMed ID: 30153975
[TBL] [Abstract][Full Text] [Related]
48. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
49. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
Tanioka H; Honda M; Tanaka C; Morita Y; Ishibashi K; Kato T; Matsuda C; Kataoka M; Satake H; Munemoto Y; Kobayashi K; Takahashi M; Nakata K; Sakamoto J; Oba K; Mishima H
Int J Clin Oncol; 2019 Jul; 24(7):836-841. PubMed ID: 30778794
[TBL] [Abstract][Full Text] [Related]
50. [Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].
Maruo H; Suzuki K; Ishikawa S; Murakami T; Higashi Y; Shoji T; Yamazaki M; Taniguchi M; Nishiyama R
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2583-6. PubMed ID: 25596052
[TBL] [Abstract][Full Text] [Related]
51. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
52. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
[TBL] [Abstract][Full Text] [Related]
53. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
